Treatment decisions in multiple sclerosis — insights from real-world observational studies

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Reviews Neurology

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrneurol.2016.188PMID 28084327
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod

  2017cited by this paper
• Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis

  2017cited by this paper
• Data quality evaluation for observational multiple sclerosis registries

  2017cited by this paper
• Contribution of different relapse phenotypes to disability in multiple sclerosis

  2017cited by this paper
• Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

  2016cited by this paper
• Integrating Randomized Comparative Effectiveness Research with Patient Care.

  2016cited by this paper
• Cautionary tales in the interpretation of observational studies of effects of clinical interventions

  2016cited by this paper
• Disease-modifying therapies and infectious risks in multiple sclerosis

  2016cited by this paper
• Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study

  2016cited by this paper
• Assessing response to interferon-β in a multicenter dataset of patients with MS

  2016cited by this paper
• Comparative efficacy of first-line natalizumab vs IFN-&bgr; or glatiramer acetate in relapsing MS

  2016cited by this paper
• Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis

  2016cited by this paper
• Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis

  2016cited by this paper
• Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis

  2016cited by this paper
• Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

  2016cited by this paper
• Recommendations for observational studies of comorbidity in multiple sclerosis

  2016cited by this paper
• Comparative efficacy of fingolimod vs natalizumab

  2016cited by this paper
• Defining secondary progressive multiple sclerosis.

  2016cited by this paper
• Bayesian evidence synthesis for exploring generalizability of treatment effects: a case study of combining randomized and non‐randomized results in diabetes

  2016cited by this paper
• Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study

  2016cited by this paper
• Immunomodulatory therapies delay disease progression in multiple sclerosis

  2016cited by this paper
• Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

  2016cited by this paper
• Observational data: Understanding the real MS world

  2016cited by this paper
• Standardizing Patient Outcomes Measurement.

  2016cited by this paper
• Comparative efficacy of switching to natalizumab in active multiple sclerosis

  2015cited by this paper
• Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

  2015cited by this paper
• Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model

  2015cited by this paper
• Can we measure long-term treatment effects in multiple sclerosis?

  2015cited by this paper
• The rise of big clinical databases

  2015cited by this paper
• The Swedish MS registry – clinical support tool and scientific resource

  2015cited by this paper
• Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

  2015cited by this paper
• Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β‐1a

  2015cited by this paper
• Disease activity in the first year predicts longer-term clinical outcomes in the pooled population of the phase III FREEDOMS and FREEDOMS II studies (P7.239)

  2015cited by this paper
• Defining high, medium and low impact prognostic factors for developing multiple sclerosis.

  2015cited by this paper
• Propensity score studies are unlikely to underestimate treatment effects in critical care medicine: a critical reanalysis.

  2015cited by this paper
• Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator

  2015cited by this paper
• Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

  2015cited by this paper
• Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

  2015cited by this paper
• Defining reliable disability outcomes in multiple sclerosis.

  2015cited by this paper
• Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

  2015cited by this paper
• Data quality monitoring and performance metrics of a prospective, population-based observational study of maternal and newborn health in low resource settings

  2015cited by this paper
• Predictors of disability worsening in clinically isolated syndrome

  2015cited by this paper
• Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.

  2015cited by this paper
• Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

  2015cited by this paper
• Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

  2015cited by this paper
• Registers of multiple sclerosis in Denmark

  2015cited by this paper
• Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.

  2015cited by this paper
• The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

  2015cited by this paper
• Assessing treatment response to interferon-β

  2014cited by this paper
• Developing and validating risk prediction models in an individual participant data meta-analysis

  2014cited by this paper
• Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

  2014cited by this paper
• Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

  2014cited by this paper
• The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials.

  2014cited by this paper
• Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

  2014cited by this paper
• Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

  2014cited by this paper
• Fingolimod after natalizumab and the risk of short-term relapse

  2014cited by this paper
• Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

  2014cited by this paper
• Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

  2014cited by this paper
• Automatic multiple sclerosis brain lesion localization and volumetry

  2014cited by this paper
• ACTRIMS-ECTRIMS MSBoston 2014: Poster Sessions 2

  2014cited by this paper
• Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

  2014cited by this paper
• Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

  2014cited by this paper
• Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis

  2014cited by this paper
• Multiple sclerosis registries in Europe – results of a systematic survey

  2014cited by this paper
• Big data: the next frontier for innovation in therapeutics and healthcare

  2014cited by this paper
• Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.

  2014cited by this paper
• Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta

  2013cited by this paper
• Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research

  2013cited by this paper
• Effectively Selecting a Target Population for a Future Comparative Study

  2013cited by this paper
• Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.

  2013cited by this paper
• Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

  2013cited by this paper
• Scoring treatment response in patients with relapsing multiple sclerosis

  2013cited by this paper
• Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

  2013cited by this paper
• A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta‐analysis

  2013cited by this paper
• Simulating from marginal structural models with time‐dependent confounding

  2012cited by this paper
• Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.

  2012cited by this paper
• The Norwegian Multiple Sclerosis Registry and Biobank

  2012cited by this paper
• Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

  2012cited by this paper
• Early predictors of non‐response to interferon in multiple sclerosis

  2012cited by this paper
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

  2012cited by this paper
• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

  2012cited by this paper
• Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.

  2012cited by this paper
• The Norwegian Multiple Sclerosis Registry and Biobank

  2012cited by this paper
• A simulation study of finite‐sample properties of marginal structural Cox proportional hazards models

  2012cited by this paper
• One‐to‐many propensity score matching in cohort studies

  2012cited by this paper
• Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

  2011cited by this paper
• A pragmatic view on pragmatic trials

  2011cited by this paper
• Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

  2011cited by this paper
• Multiple Sclerosis Therapeutics: The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis

  2011cited by this paper
• How to assess the external validity of therapeutic trials: a conceptual approach.

  2010cited by this paper
• observational studies: propensity score analysis of non-randomized data.

  2009cited by this paper
• High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data

  2009cited by this paper
• Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis

  2009cited by this paper
• Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

  2009cited by this paper
• Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• The Relative Ability of Different Propensity Score Methods to Balance Measured Covariates Between Treated and Untreated Subjects in Observational Studies

  2009cited by this paper
• A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers

  2009cited by this paper
• Measures in the first year of therapy predict the response to interferon β in MS

  2009cited by this paper
• Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

  2008cited by this paper

• Real-world experience of cladribine treatment in relapsing multiple sclerosis: A Romanian multicenter nationwide study.

  2026cites this paper
• Leveraging real-world data in evidence-based caries research: a meta-epidemiological study

  2026cites this paper
• Effectiveness and safety of ofatumumab in treatment-naive and oral DMT-switched multiple sclerosis patients: a multicenter observational study in China.

  2025cites this paper
• Big multiple sclerosis data network: novel modelling approaches for real-world data analysis

  2025cites this paper
• Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study.

  2025cites this paper
• Delays in treatment initiation for patients with relapsing-remitting multiple sclerosis—A nationwide population-based study

  2025cites this paper
• Integrating big data and artificial intelligence to predict progression in multiple sclerosis: challenges and the path forward

  2025cites this paper
• Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis

  2025cites this paper
• Explainable time-to-progression predictions in multiple sclerosis

  2025cites this paper
• Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD.

  2025cites this paper
• Rituximab for people with multiple sclerosis.

  2025cites this paper
• Laser treatment for urinary incontinence in elite female athletes analyzed using a discrete mathematics approach

  2025cites this paper
• CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

  2025cites this paper
• Challenges in Diagnosis and Therapeutic Strategies in Late-Onset Multiple Sclerosis

  2024cites this paper
• Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register.

  2024cites this paper
• Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab

  2024cites this paper
• Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

  2024cites this paper
• The arisal of data spaces: why I am excited and worried

  2024cites this paper
• Psychometric properties of patient-reported outcome measures, measuring fatigue in patients with multiple sclerosis, a systematic review.

  2024cites this paper
• Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network

  2024cites this paper
• Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosis.

  2024cites this paper
• Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study

  2024cites this paper
• Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment

  2024cites this paper
• Big Multiple Sclerosis Data network: an international registry research network

  2024cites this paper
• Real‐world persistence of multiple sclerosis disease‐modifying therapies

  2024cites this paper
• Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.

  2024cites this paper
• Recent Advances in Biosensors for Diagnosis of Autoimmune Diseases

  2024cites this paper
• Representing and utilizing clinical textual data for real world studies: An OHDSI approach

  2023cites this paper
• Predictors of treatment switching in the Big Multiple Sclerosis Data Network

  2023cites this paper
• Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

  2023cites this paper
• Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS)

  2023cites this paper
• Observational studies of treatment effectiveness in neurology

  2023cites this paper
• Leveraging Real-World Evidence and Observational Studies in Treating Multiple Sclerosis.

  2023cites this paper
• Impact of aging on treatment considerations for multiple sclerosis patients

  2023cites this paper
• Predictors of therapeutic failure in multiple sclerosis: a Brazilian center’s experience.

  2023cites this paper
• Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.

  2023cites this paper
• Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis

  2023cites this paper
• Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers

  2023cites this paper
• Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis

  2022cites this paper
• Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.

  2022cites this paper
• High persistence and low adverse events burden in cladribine treated MS patients from Argentina.

  2022cites this paper
• Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece

  2022influential citation
• Interrogating large multiple sclerosis registries and databases: what information can be gained?

  2022cites this paper
• Critères d’évaluation d’efficacité d’un traitement de première ligne dans la sclérose en plaques en pratique courante

  2022cites this paper
• Dimethyl Fumarate in Multiple Sclerosis Patients: A Real World Study

  2022cites this paper
• A Prospective Viewpoint on Neurological Diseases and Their Biomarkers

  2022cites this paper
• Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)

  2022cites this paper
• The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary

  2022cites this paper
• DNND_A_313825 61..73

  2022cites this paper
• Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data

  2022cites this paper
• Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

  2022cites this paper
• Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal.

  2021cites this paper
• CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab

  2021cites this paper
• Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

  2021cites this paper
• Azathioprine for people with multiple sclerosis

  2021cites this paper
• Ocrelizumab treatment in multiple sclerosis: A Danish population‐based cohort study

  2021cites this paper
• Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data

  2021cites this paper
• Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation.

  2021cites this paper
• Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

  2021cites this paper
• First‐line therapies in late‐onset multiple sclerosis: An Italian registry study

  2021cites this paper
• Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis

  2021cites this paper
• Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry

  2021cites this paper
• Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

  2021cites this paper
• Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening

  2021cites this paper
• Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies

  2021cites this paper
• Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry

  2021influential citation
• Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.

  2021cites this paper
• The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis

  2021cites this paper
• Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement

  2021cites this paper
• Rituximab for people with multiple sclerosis.

  2021cites this paper
• Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network

  2021cites this paper
• Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network

  2021cites this paper
• Late-onset MS is associated with an increased rate of reaching disability milestones

  2021cites this paper
• Predicting the postoperative blood coagulation state of children with congenital heart disease by machine learning based on real-world data

  2021cites this paper
• Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

  2021cites this paper
• Assessing long-term effectiveness of MS treatment — a matter of debate

  2021cites this paper
• When does a heap become a heap?

  2021cites this paper
• Machine Learning Use for Prognostic Purposes in Multiple Sclerosis

  2021cites this paper
• Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation

  2021cites this paper
• Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

  2021cites this paper
• Improving MS patients' understanding of treatment risks and benefits in clinical consultations: A randomised crossover trial.

  2021cites this paper
• Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate

  2021cites this paper
• Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study

  2020cites this paper
• Technology-enabled assessments to enhance multiple sclerosis clinical care and research.

  2020cites this paper
• Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?

  2020cites this paper
• Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM)

  2020cites this paper
• A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-β1a in multiple sclerosis patients.

  2020cites this paper
• Blood neurofilament light levels segregate treatment effects in multiple sclerosis

  2020cites this paper
• Socioeconomic status and multiple sclerosis outcome

  2020cites this paper
• Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy

  2020cites this paper
• Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

  2020cites this paper
• First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.

  2020cites this paper
• Comparison of Placebos and Propensity Score Adjustment in Multiple Sclerosis Nonrandomized Studies.

  2020cites this paper
• Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015–2017 Prevalence

  2020cites this paper
• BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab.

  2020cites this paper
• Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis.

  2020cites this paper
• Long-term Follow-up of Relapsing-Remitting Multiple Sclerosis

  2020cites this paper
• Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina

  2020cites this paper
• Comparative effectiveness studies in multiple sclerosis.

  2020cites this paper
• Data Collection in Multiple Sclerosis: The MSDS Approach

  2020cites this paper